Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers

Valenta Pharm

Status: Completed

Conditions: Nausea; Pregnancy Related

Treatments: Drug: Doxylamine + Pyridoxine

Study type: Interventional

Funder types: Industry

Identifiers

NCT05498233

DIP-05-01-2022

Details and patient eligibility

About

The study aimed for:

1. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), in healthy volunteers in fasted conditions.
2. Comparative evaluation of the safety of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSK, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), based on the analysis of adverse events (AEs).

Enrollment: 28 patients

Sex: Female

Ages: 18 to 49 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study before any of the study procedures.
2. Women of reproductive age (18 to 49 years inclusive, according to World Health Organization criteria).
3. Verified diagnosis "healthy" (absence of abnormalities according to clinical, laboratory, instrumental methods of examination stipulated by the protocol).
4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 139 mmHg, diastolic blood pressure (DBP) from 60 to 89 mmHg (inclusive).
5. Heart rate (HR) from 60 to 90 bpm (inclusive).
6. Respiratory rate (HR) from 12 to 18 bpm (inclusive).
7. Body temperature of 36 to 36.9°C (inclusive).
8. Body mass index (BMI) is 18.5 ≤ BMI ≤ 30 kg/m2, and the body weight must be ≥ 45 kg.
9. Consent to use adequate methods of contraception throughout the study and for 30 days after completion, negative pregnancy test.
10. Volunteers must behave adequately, coherent speech must be observed.

Exclusion criteria

1. A history of allergic reactions.
2. Drug intolerance of active and/or excipients included in the study drugs in the anamnesis.
3. Chronic diseases of the cardiovascular, lymphatic, respiratory, nervous, endocrine, digestive, musculoskeletal, covering, immune systems, as well as of the urogenital system and hematopoietic organs.
4. Values of standard laboratory and instrumental indices beyond the limits of local laboratory norms.
5. History of gastrointestinal surgery (except appendectomy at least 1 year before screening).
6. Diseases/conditions that the investigator believes may affect the absorption, distribution, metabolism, or excretion of the study medication.
7. Acute infectious disease less than 4 weeks prior to screening.
8. Taking drugs that have a significant effect on hemodynamics and drugs that affect liver function (barbiturates, benzodiazepines, omeprazole, cimetidine, etc.) for less than one month before screening.
9. Regular intake of drugs less than 2 weeks before screening and one-time intake of drugs less than 7 days before screening.
10. Donating blood or plasma less than 3 months before the screening visit.
11. Use of hormonal contraceptives less than 2 months before the screening visit.
12. Using depot injections of any medications less than 3 months prior to the screening visit.
13. Pregnancy or lactation, positive pregnancy test.
14. Participation in another clinical trial less than 3 months before screening or concurrently with this study.
15. Taking more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 ml of beer, 150 ml of wine, or 40 ml of spirits) in the week in the last month before inclusion in the study or anamnestic evidence of alcoholism, drug abuse, or medicine abuse.
16. Smoking.
17. Positive blood tests for antibodies to human immunodeficiency virus (HIV) type 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens, laboratory examination of biomaterial (nasopharyngeal swab) for SARS-Cov-2 RNA (COVID-19).
18. Clinically significant abnormalities on electrocardiogram (ECG).
19. Positive urinalysis for narcotics and powerful drugs.
20. Positive breath alcohol vapor test.
21. Scheduling an inpatient stay during the study period, for any reason other than hospitalization required by this protocol.
22. Failure or inability to comply with protocol requirements, perform protocol-prescribed procedures, diet, and activity regimen.
23. Observance of a religious fast or special diet (e.g., vegetarian, vegan).
24. Other conditions that, in the opinion of the Investigator, preclude a volunteer from enrolling in the study or may result in early withdrawal from the study, including special lifestyles (night work, extreme physical activity).

Withdrawal criteria:

1. The volunteer's refusal to further participate in the study.
2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.).
3. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.).
4. Volunteers included in the study in violation of the inclusion/inclusion criteria.
5. Development of a severe and/or serious adverse event (AE) in a volunteer during the study.
6. Missing 2 or more consecutive blood samples or 3 or more blood samples during one Period of the pharmacokinetic portion of the study.
7. Occurrence of vomiting/diarrhea within 24 h of study drug administration (the choice of time interval is based on the tmax parameter value for doxylamine and pyridoxal-5-phosphate not exceeding 7.2 ± 1.9 and 11.7 ± 5.3 h, respectively, according to the manufacturer of the reference drug).
8. Positive urine test for narcotic substances and potent drugs.
9. Positive breath alcohol vapor test.
10. A positive pregnancy test.
11. Positive test for SARS-Cov-2 RNA (COVID-19);
12. Other causes occurring in the course of the study that prevent the study from being conducted according to the protocol.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

RT-sequence

Other group

Description:

Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2

Treatment:

Drug: Doxylamine + Pyridoxine

TR-sequence

Other group

Description:

Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.

Treatment:

Drug: Doxylamine + Pyridoxine